Compared with healthy individuals, early-stage (I and II) NSCLC patients had similar concentrations of SLC1A5 while late-stage treatment naïve patients with EGFR mutation-positive NSCLC had slightly elevated SLC1A5. This evidence concerns the gene EGFR and non-small cell lung carcinoma.